769 related articles for article (PubMed ID: 30882868)
1. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
2. Long-term disability progression of pediatric-onset multiple sclerosis.
McKay KA; Hillert J; Manouchehrinia A
Neurology; 2019 Jun; 92(24):e2764-e2773. PubMed ID: 31092624
[TBL] [Abstract][Full Text] [Related]
3. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
4. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
[TBL] [Abstract][Full Text] [Related]
5. Epilepsy in multiple sclerosis: A nationwide population-based register study.
Burman J; Zelano J
Neurology; 2017 Dec; 89(24):2462-2468. PubMed ID: 29117950
[TBL] [Abstract][Full Text] [Related]
6. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
[TBL] [Abstract][Full Text] [Related]
7. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
Sharmin S; Roos I; Malpas CB; Iaffaldano P; Simone M; Filippi M; Kubala Havrdova E; Ozakbas S; Brescia Morra V; Alroughani R; Zaffaroni M; Patti F; Eichau S; Salemi G; Di Sapio A; Inglese M; Portaccio E; Trojano M; Amato MP; Kalincik T; ;
Lancet Child Adolesc Health; 2024 May; 8(5):348-357. PubMed ID: 38547883
[TBL] [Abstract][Full Text] [Related]
9. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
10. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
11. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
12. Self-reported levels of education and disability progression in multiple sclerosis.
D'hooghe MB; Haentjens P; Van Remoortel A; De Keyser J; Nagels G
Acta Neurol Scand; 2016 Dec; 134(6):414-419. PubMed ID: 27761897
[TBL] [Abstract][Full Text] [Related]
13. The impairment of the functional system and fatigue at the onset of the disease predict reaching disability milestones in relapsing-remitting multiple sclerosis differently in female and male patients.
Ivaniuk A; Solodovnikova Y; Marusich T; Son A
Acta Neurol Belg; 2021 Dec; 121(6):1699-1706. PubMed ID: 32997326
[TBL] [Abstract][Full Text] [Related]
14. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
[TBL] [Abstract][Full Text] [Related]
15. Modelling the natural history of primary progressive multiple sclerosis.
Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
[TBL] [Abstract][Full Text] [Related]
16. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
[No Abstract] [Full Text] [Related]
17. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
[TBL] [Abstract][Full Text] [Related]
18. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
[TBL] [Abstract][Full Text] [Related]
19. Clinical course of multiple sclerosis: A nationwide cohort study.
Manouchehrinia A; Beiki O; Hillert J
Mult Scler; 2017 Oct; 23(11):1488-1495. PubMed ID: 27956559
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
Mouresan EF; Mentesidou E; Berglund A; McKay KA; Hillert J; Iacobaeus E
Neurology; 2024 Mar; 102(6):e208051. PubMed ID: 38394472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
